We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksByotrol Regulatory News (BYOT)

Share Price Information for Byotrol (BYOT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.125
Bid: 0.05
Ask: 0.20
Change: 0.00 (0.00%)
Spread: 0.15 (300.00%)
Open: 0.125
High: 0.125
Low: 0.125
Prev. Close: 0.125
BYOT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

First US Retail Trial with Target

17 May 2018 07:00

RNS Number : 3364O
Byotrol PLC
17 May 2018
 

 

 

17th May, 2018

Byotrol plc

("Byotrol" or the "Company") 

 

FURTHER PROGRESS IN THE US

 

MASS MARKET RETAIL TRIAL WITH TARGET

 

 

Byotrol plc, the specialist anti-microbial technology company, is pleased to announce that it has secured its first mass market retail trial in the US, for its 24-hour germ-kill surface sanitizer 'Byotrol24'.

 

The trial is due to take place over approximately 10-12 weeks at the national retailer Target. We are expecting the trial to start next month in approximately 10% of Target's 1,829 stores, following which Target will decide whether it wishes to roll-out into nationwide distribution.

 

This progress follows on closely from the Company having completed individual US State product registration earlier this month. Byotrol24 received formal approval from the US Environmental Protection Agency in June 2017.

 

 

 

David Traynor, Chief Executive of Byotrol plc comments:

 

"This is really good news for Byotrol. Target Corporation is one of the leading general merchandise retailers in the US and is well-known for innovation and design; it is a perfect retail match for our brand and an excellent first step in pursuing our US commercialisation ambitions."

 

 

 

Enquiries:

David Traynor - Chief Executive, Byotrol plc 01925 742 000

David Paton - Investor Relations 07714 190 474

 

 

finnCap Ltd 020 7220 0500 (Nominated Adviser & Broker)

Geoff Nash/Kate Bannatyne - Corporate Finance

Richard Chambers - Corporate Broking

 

The information communicated in this announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No. 596/2014.

 

Notes to Editors:

 

Byotrol plc (BYOT.L), quoted on AIM, is a specialist developer of residual antimicrobial technologies, identifying, developing, formulating and commercialising cutting-edge antimicrobial solutions.

 

Our patented suite of technologies deliver powerful broad-spectrum efficacy with residual performance optimised against commonly occurring and industry-specific pathogens.

 

Founded in 2005, the Company has developed advanced antimicrobial technologies that create easier, safer and cleaner lives for everyone.

 

For more information, please go to www.byotrol.co.uk

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
CNTLLFIRELIRLIT
Date   Source Headline
17th May 20187:00 amRNSFirst US Retail Trial with Target
10th May 20184:32 pmRNSHolding(s) in Company
10th May 20187:00 amRNSState approval in US
23rd Apr 20183:07 pmRNSHolding(s) in Company
11th Apr 20187:00 amRNSTrading Statement
26th Feb 20183:10 pmRNSHolding(s) in Company
18th Jan 20187:00 amRNSDirector Dealing
14th Dec 20177:01 amRNSKey US Hire & Grant of Options
14th Dec 20177:00 amRNSInterim Results
7th Dec 20177:00 amRNSNotice of Results
10th Nov 20177:00 amRNSGrant of Options & Director/PDMR Shareholdings
28th Sep 201711:49 amRNSResult of AGM
6th Sep 201712:48 pmRNSHolding(s) in Company
6th Sep 201711:37 amRNSForm 8.3 - Byotrol Plc
6th Sep 201711:31 amRNSHolding(s) in Company
5th Sep 20174:37 pmRNSHolding(s) in Company
5th Sep 20174:36 pmRNSHolding(s) in Company
5th Sep 20174:35 pmRNSHolding(s) in Company
4th Sep 201711:57 amRNSResult of General Meeting
31st Aug 20177:00 amRNSResult of Open Offer
30th Aug 20179:24 amRNSPosting of Annual Report and Notice of AGM
29th Aug 20171:19 pmRNSConversion of Loan Notes and Issue of Equity
17th Aug 20172:31 pmRNSHolding(s) in Company
8th Aug 20174:47 pmRNSPlacing & Open Offer Timetable
7th Aug 20179:44 amRNSHolding(s) in Company
3rd Aug 201712:00 pmRNSResult of Proposed Fundraising
3rd Aug 20177:01 amRNSProposed Fundraising
3rd Aug 20177:00 amRNSFinal Results
13th Jun 20177:00 amRNSEPA Approval
13th Mar 20177:00 amRNSAcquisition
6th Feb 20177:00 amRNSDirector Dealing
1st Feb 20177:00 amRNSBoard changes and issue of options
13th Dec 20167:00 amRNSInterim Results
7th Dec 201612:29 pmRNSNotice of Interim Results
14th Oct 20167:00 amRNSGrant of Options and Director Shareholdings
12th Oct 20167:00 amRNSTransfer of Convertible Loan Notes
30th Sep 20163:16 pmRNSResult of Noteholders Meeting
22nd Sep 20164:51 pmRNSResult of AGM
9th Sep 20167:00 amRNSProposed Revision to Loan Notes
18th Aug 20167:00 amRNSFinal Results
8th Jul 20167:00 amRNSTrading Update and Notice of AGM
25th Feb 20167:00 amRNSTrading Statement
19th Feb 20163:34 pmRNSDirector/PDMR Shareholding
3rd Dec 20158:00 amRNSGrant of Options
3rd Dec 20157:00 amRNSInterim Results
9th Sep 201512:06 pmRNSHolding(s) in Company
8th Sep 20154:05 pmRNSResult of AGM and Completion of Placing
24th Aug 20151:57 pmRNSHolding(s) in Company
20th Aug 20151:00 pmRNSPlacing and Subscription to raise £1.4 million
14th Aug 20157:00 amRNSPosting of Annual Report and Notice of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.